Founded in Europe, EKF Diagnostics is a global healthcare company specializing in Point-of-Care (POC) and Central Laboratory medical technology. The company's core mission is to empower healthcare providers with innovative diagnostic tools and biotechnology solutions that facilitate informed clinical decisions. EKF's product portfolio includes tests for hemoglobin, HbA1c, glucose, lactate, and various chemistry reagents, catering to both POC and central lab settings. Their market focus spans across the globe, aiming to enhance patient care through advanced diagnostic technologies.
EKF Diagnostics is listed on the London Stock Exchange's AIM market, reflecting its significant presence and credibility in the industry. The company has achieved notable milestones in the development and distribution of cutting-edge medical technologies that have positively impacted healthcare delivery worldwide. By providing reliable and efficient diagnostic solutions, EKF has established itself as a key player in the global diagnostics and biotechnology sectors, contributing to improved patient outcomes and streamlined clinical workflows.
